FTC (US Federal Trade Commission) blocks Abbott's deal with Alza over antitrust concerns
This article was originally published in Clinica
Abbott's proposed $7.3 billion acquisition of drug delivery company Alza has collapsed after the two companies failed to satisfy the US Federal Trade Commission's antitrust concerns. The development is the second serious blow for Abbott in six weeks, following its $100 million settlement with the FDA over manufacturing issues.
You may also be interested in...
Trump administration effort to reduce drug prices by curtailing agency program requiring new approvals for some old products undermines FDA’s role in policing the safety of prescription drugs, experts say.
The maker of prestige-inspired cosmetics at value prices follows its TikTok viral success by teaming with Kathleen Belsten, aka Loserfruit, the second most-followed female gamer on the Amazon-owned livestreaming platform Twitch.
As distribution of Regeneron’s monoclonal antibody treatment for coronavirus begins, OWS officials worry about provider confusion with Lilly’s product due to differences in preparation and administration.